Bilirubin Can Be Used as a Prognostic Factor for Lung Adenocarcinoma Patients with EGFR Mutations.

EGFR-TKIs bilirubin lung adenocarcinoma prognosis progression-free survival

Journal

OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322

Informations de publication

Date de publication:
2020
Historique:
received: 24 06 2020
accepted: 07 10 2020
entrez: 5 11 2020
pubmed: 6 11 2020
medline: 6 11 2020
Statut: epublish

Résumé

Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor ( LAC cases diagnosed and undergone EGFR-TKIs targeted therapy at The First Affiliated Hospital of Zhengzhou University between 2013 and 2015 were retrospectively reviewed. A total of 180 patients were studied according to inclusion and exclusion criteria. Follow-up data were collected for all patients until the disease progressed. Univariate analysis showed that the levels of pretreatment total bilirubin (TBIL), indirect bilirubin (IBIL) and direct bilirubin (DBIL) were related to PFS (all This study confirms that bilirubin can predict the prognosis of LAC patients who had undergone EGFR-TKIs targeted therapy.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (
PATIENTS AND METHODS METHODS
LAC cases diagnosed and undergone EGFR-TKIs targeted therapy at The First Affiliated Hospital of Zhengzhou University between 2013 and 2015 were retrospectively reviewed. A total of 180 patients were studied according to inclusion and exclusion criteria. Follow-up data were collected for all patients until the disease progressed.
RESULTS RESULTS
Univariate analysis showed that the levels of pretreatment total bilirubin (TBIL), indirect bilirubin (IBIL) and direct bilirubin (DBIL) were related to PFS (all
CONCLUSION CONCLUSIONS
This study confirms that bilirubin can predict the prognosis of LAC patients who had undergone EGFR-TKIs targeted therapy.

Identifiants

pubmed: 33149620
doi: 10.2147/OTT.S266477
pii: 266477
pmc: PMC7605630
doi:

Types de publication

Journal Article

Langues

eng

Pagination

11089-11095

Informations de copyright

© 2020 Geng et al.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

JAMA. 2011 Feb 16;305(7):691-7
pubmed: 21325185
Oncotarget. 2017 Dec 12;9(1):892-900
pubmed: 29416664
J Clin Oncol. 2005 Oct 1;23(28):6829-37
pubmed: 15998907
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
J Clin Oncol. 2005 Apr 10;23(11):2513-20
pubmed: 15738541
Cancer Epidemiol. 2015 Oct;39(5):763-8
pubmed: 26159684
Int J Cancer. 2004 Nov 10;112(3):433-45
pubmed: 15382069
Clin Cancer Res. 2015 Jan 1;21(1):193-200
pubmed: 25336700
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
J Thorac Oncol. 2016 Sep;11(9):1433-46
pubmed: 27448762
BMC Cancer. 2009 May 20;9:155
pubmed: 19457231
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Int J Cancer. 2017 Apr 1;140(7):1645-1652
pubmed: 28006834
Cancer Causes Control. 2001 Dec;12(10):887-94
pubmed: 11808707
Br J Cancer. 2006 Mar 13;94(5):637-41
pubmed: 16479253
J Cancer Res Clin Oncol. 2013 Apr;139(4):681-9
pubmed: 23315099
Clin Cancer Res. 2007 May 15;13(10):2890-6
pubmed: 17504988
Clin Cancer Res. 2006 Oct 1;12(19):5764-9
pubmed: 17020982
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
Eur J Cancer. 2009 Jan;45(2):248-60
pubmed: 19095437
N Engl J Med. 2008 Sep 25;359(13):1367-80
pubmed: 18815398
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Hepatology. 2004 Oct;40(4):827-35
pubmed: 15382174
Clin Chem. 1995 Oct;41(10):1504-8
pubmed: 7586525
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
Biochem Biophys Res Commun. 2006 Apr 21;342(4):1279-83
pubmed: 16516158
PLoS One. 2013 Dec 27;8(12):e83069
pubmed: 24386144
Science. 1987 Feb 27;235(4792):1043-6
pubmed: 3029864
Lancet Oncol. 2015 Apr;16(4):e165-72
pubmed: 25846096
Semin Respir Crit Care Med. 2000;21(5):365-73
pubmed: 16088748
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Lung Cancer. 2014 Sep;85(3):457-64
pubmed: 25043641
Carcinogenesis. 2015 Feb;36(2):243-8
pubmed: 25524924
J Clin Oncol. 2005 Apr 10;23(11):2556-68
pubmed: 15767641
J Clin Oncol. 2011 Aug 20;29(24):3316-21
pubmed: 21788562

Auteurs

Yimeng Geng (Y)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Yeling Mei (Y)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Ying Xi (Y)

Department of Radiotherapy, Puyang Oilfield General Hospital, Puyang, Henan, People's Republic of China.

Junlin Yu (J)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Ke Meng (K)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Tengfei Zhang (T)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Wang Ma (W)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Classifications MeSH